You are here

VRTX

$166.58

0.00%

Investor Relations

News & Events

Filter Releases
 
Press Releases
Date Title and Summary View
Feb 3, 2010
CAMBRIDGE, Mass., Feb 03, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from a preliminary analysis of data from a 28-day Phase 2a clinical trial of VX-809 in patients with cystic fibrosis (CF) who are homozygous for the F508del mutation. VX-809, an oral investigational ...
Oct 18, 2010
CAMBRIDGE, Mass., Oct 18, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the initiation of a Phase 2a clinical trial that will evaluate multiple combinations of VX-770 and VX-809, investigational oral cystic fibrosis transmembrane conductance regulator (CFTR) modulators for...
Nov 17, 2010
-Treatment with VX-770 resulted in improvements in lung function and markers of disease- -There were no discontinuations of treatment due to adverse events- -Late-stage Phase 3 clinical trials for VX-770 ongoing- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- In...
Feb 23, 2011
- Relative mean improvement in lung function of approximately 17% from baseline compared to placebo achieved by people treated with VX-770; mean absolute improvement from baseline of approximately 10.5% compared to placebo; both measures through 24 and 48 weeks - - Significant improvements in all ...
Mar 29, 2011
-Mean relative improvement in lung function of 17.4% and mean absolute improvement of 12.5% from baseline compared to placebo in children treated with VX-770- - No discontinuations due to adverse events through 24 weeks - -Vertex on track to submit regulatory applications for the ...
Apr 7, 2011
-Expanded collaboration supports development of a second corrector, VX-661, and accelerated discovery and development of next-generation correctors- -Phase 2 study of VX-661 planned for 2011 in people with CF who have the F508del mutation- CAMBRIDGE, Mass.--(BUSINESS...
Jun 9, 2011
-13.17 mmol/L reduction in sweat chloride in one arm supports further evaluation of a combination approach to treating the root cause of cystic fibrosis- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced interim results from the f...
Jun 10, 2011
- Complete data presented at ECFS showed improvements in lung function and reductions in sweat chloride observed at week two of treatment were sustained through 48 weeks - - Vertex also announces that 48-week data from the ENVISION study of VX-770 among children ages 6 to 11 years are consistent w...
Oct 3, 2011
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that nine abstracts from its cystic fibrosis (CF) research program, which is aimed at discovering and developing medicines that target the underlying cause of CF, will be presented at the 25th Annual North Ameri...
Oct 19, 2011
-- Accelerated assessment of KALYDECO granted by the European Medicines Agency; MAA submission planned in EU by the end of October -- -- Phase 3 registration studies of KALYDECO showed significant improvements in lung function and other measures of disease among a subset of people with CF -- ...
Nov 2, 2011
- Study shows that treating CF by targeting the underlying cause of the disease leads to significant clinical benefits among people with the G551D mutation - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced that the New England Jo...
Nov 3, 2011
- New data at North American CF Conference showed a reduction in sweat chloride when KALYDECO was added to VX-809 in people with the F508del mutation — - Part 2 of study now enrolling patients - ANAHEIM, Calif.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorpor...
Nov 3, 2011
- Additional presentations at the North American CF Conference include data from PERSIST that showed sustained safety and efficacy of KALYDECO through 60 weeks of treatment among adolescents and adults treated in the Phase 3 STRIVE study - ANAHEIM, Calif.--(BUSINESS WIRE)-- Vertex P...
Dec 15, 2011
-- Six-month review date of April 18, 2012 set by FDA -- -- European Medicines Agency accepts KALYDECO regulatory submission for accelerated assessment -- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the ...
Jan 31, 2012
- FDA approval received 3 months after submission of New Drug Application - - KALYDECO approved to treat people with CF who have a specific genetic mutation - - Vertex launches a comprehensive financial assistance and patient support program - ...
Page:
...
Next Last